Spectrin alpha chain, non-erythrocytic 1 (SPTAN1) (SPTAN1)

Spectrin alpha chain, non-erythrocytic 1 (SPTAN1) encodes alpha-II spectrin, a major scaffolding protein essential for the structural integrity of the submembrane cytoskeleton in non-erythroid cells, particularly within the central nervous system [1, 2]. It plays a critical role in organizing transmembrane proteins, facilitating cell adhesion, and participating in signal transduction and DNA repair processes [1]. Mutations in the SPTAN1 gene, often occurring de novo, are the primary cause of Early Infantile Epileptic Encephalopathy type 5 (EIEE5), a severe condition characterized by early-onset seizures, microcephaly, and profound developmental delay [3]. While no drugs are currently FDA-approved to target SPTAN1 mRNA, it is a subject of intense research for genetic therapies, including antisense oligonucleotides (ASOs) designed to mitigate the effects of dominant-negative or gain-of-function mutations [4]. In the context of oncology, SPTAN1 has been identified as a potential biomarker and is involved in the TGF-beta signaling pathway, influencing tumor progression in cancers such as colorectal and lung cancer [5]. Therapeutic strategies targeting SPTAN1 mRNA aim to modulate protein levels to restore cytoskeletal stability or inhibit pathological signaling in disease states. The essential nature of the protein makes precise modulation of its mRNA levels a significant therapeutic challenge to avoid haploinsufficiency or toxicity.

Other names

Alpha-II spectrinFodrin alpha chainNEASSPTA2EIEE5

Antisense oligonucleotide-mediated knockdown or splice modulation